Document:

EX-10.10

 Exhibit 10.10 

BOARD OBSERVER AND INDEMNIFICATION AGREEMENT 

This Board Observer and Indemnification Agreement, dated as of the 5th day of November, 2013 (this “Agreement”), is made by
and among Griffin Capital Essential Asset REIT, Inc., a Maryland corporation (the “Company”), Warren DeHaan (the “Observer”), SPT Griffin Holdings, LLC (the “Investor”) and Starwood
Property Trust, Inc. (the “Parent”). 
 WHEREAS, the Investor has provided an approximately $250 million investment in
the Company’s operating partnership (the “Investment”) pursuant to that certain Series A Cumulative Redeemable Exchangeable Preferred Unit Purchase Agreement by and among the Company, Griffin Capital Essential Asset REIT
Operating Partnership, L.P., and the Parent, dated November 5, 2013 (the “Unit Purchase Agreement”); 
 WHEREAS, as
part of the Investment, the Company has agreed that Investor may appoint a non-voting observer who will be permitted to attend meetings of the Company’s Board of Directors and Committees, with such further rights and upon such further
restrictions as set forth in that certain Investor Rights Agreement by and between the Company and Investor dated November 5, 2013 (the “Investor Rights Agreement”); 

WHEREAS, Investor has appointed Observer as the non-voting observer pursuant to the terms of the Investor Rights Agreement; 

NOW, THEREFORE, in consideration of Investor’s Investment, and in accordance with the terms of the Investor Rights Agreement, the Company
hereby agrees to indemnify Observer subject to the following terms: 
 1.    Board Observer Rights. 

(a)    The Company agrees that it will invite Observer to attend, in a nonvoting observer capacity, meetings of the
Company’s Board of Directors and any and all Committees thereof for the sole purpose of permitting Observer and its affiliates, Investor and Parent (collectively, with their respective or collective affiliates, the “Starwood
Companies”) to have current information with respect to the affairs of the Company and the actions taken by the Board of Directors (the “Approved Purposes”). Observer shall have the right to be heard at any such meeting,
but in no event shall the Observer be deemed to be a member of the Board or such Committees or have the right to vote on any matter under consideration by the Board or such Committees or otherwise have any power to cause the Company to take, or not
to take, any action. As a nonvoting observer, Observer will also be provided copies of all notices, minutes, consents, and all other materials or information that is provided to the directors with respect to a meeting or any written consent in
lieu of meeting (except to the extent Observer has been excluded therefrom pursuant to clause (c) below). 

(b)    If a meeting of the Board or any of the Committees is conducted via telephone or other electronic medium (e.g.,
videoconference), Observer may attend such meeting via the same medium; provided, however, that it shall be a material breach of this Agreement for anyone other than (i) Observer, (ii) a successor observer, if one has been appointed by the
Investor pursuant to Section 2.1(a) of the Investor Rights Agreement, or (iii) an observer designee, if one has been designated by the Investor pursuant to Section 2.1(b) of the Investor Rights Agreement, to attend or participate in
any way in such meeting, directly or indirectly, without the Company’s express prior written consent. 

(c)    Notwithstanding the foregoing, the Company may exclude Observer from access to any material or meeting or portion
thereof if (i) the Company believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege between the Company and its 

 
counsel; or (ii) such portion of a meeting is an executive session limited solely to independent director members of the Board of Directors, independent auditors and/or legal counsel, as the
Board of Directors may designate and the Observer would not meet the then-applicable standards for independence of an independent director member of the Board of Directors. 

(d)    The Company shall reimburse the Observer on a quarterly basis for the reasonable out-of-pocket expenses incurred by
the Observer in connection with attendance at Board and Committee meetings. 
 (e)    The rights described in this
Section 1 shall terminate upon (i) any material violation of the terms of this Agreement by any of the Starwood Companies and/or Observer, (ii) the death or disability of Observer, (iii) termination of the Investor’s right
to appoint and maintain an Observer to the Company’s Board as provided in the Investor Rights Agreement, or (iv) any separation by Observer from the Starwood Companies. 

2.    Confidential Treatment of Company Confidential Information. 

(a)    In consideration of the Company’s disclosure to Observer, on his own behalf and as authorized agent for the
Starwood Companies, of information which is not publicly available concerning the Company for the Approved Purposes, Observer and the Starwood Companies jointly and severally agree that this Agreement will apply to all information, in any form
whatsoever, disclosed or made available to Observer and the Starwood Companies (collectively, the “Recipient”) concerning the Company, its affiliates and/or the Approved Purposes (“Confidential Information”). 

(b)    Except as otherwise provided herein, Recipient agrees: (i) to hold Confidential Information in strict
confidence and trust and to act in a fiduciary manner with respect to all Confidential Information; (ii) not to disclose Confidential Information to any third parties; and (iii) not to use any Confidential Information for any purpose
except for the sole purpose of the Approved Purposes. Recipient may disclose the Confidential Information to its responsible employees, agents, advisors, affiliates and representatives with a bona fide need to know
(“Representatives”), but only to the extent necessary for the Approved Purposes. Recipient agrees to instruct all such Representatives not to disclose such Confidential Information to third parties without the prior written
permission of the Company. Recipient will, at all times, remain liable under the terms of this Agreement for any unauthorized disclosure or use of Confidential Information by any of its Representatives. 

3.    Exempted Disclosure. The foregoing restriction on the use and nondisclosure of Confidential Information will
not include information which: (i) is, or hereafter becomes, through no act or failure to act on the part of the Recipient, generally known or available to the public; (ii) was acquired by the Recipient before receiving such information
from the Company, without restriction as to use or disclosure; (iii) is hereafter furnished to the Recipient by a third party, without restriction as to use or disclosure; (iv) such information was independently developed by Recipient; or
(v) is required to be disclosed pursuant to judicial process or court order, provided, that to the extent permitted by law, rule or regulation and reasonably practicable under the circumstances, the Recipient gives the Company prompt notice of
such required disclosure so that the Company may challenge the same. 
 4.    Return of Confidential Information.
Upon request of the Company, the Recipient will promptly: (i) return to the Company all physical materials containing or consisting of Confidential Information and all hard copies thereof; and (ii) destroy all electronically stored
Confidential Information in Recipient’s possession or control. Recipient may retain in its confidential files one copy of any item of Confidential Information in order to comply with any legal, compliance or regulatory requirements. Any
Confidential Information that is not returned or destroyed, including, without limitation, any oral 

 
Confidential Information, and all notes, analyses, compilations, studies or other documents prepared by or for the benefit of the Recipient from such information, will remain subject to the
confidentiality obligations set forth in this Agreement indefinitely. 
 5.    Disclaimer. All Confidential
Information is provided to Recipient “as is” and the Company does not make any representation or warranty as to the accuracy or completeness of the Confidential Information or any component thereof. The Company will have no liability to
Recipient resulting from the reliance on the Confidential Information by Recipient or any third party to whom such Confidential Information is disclosed. 

6.    Company Ownership of Confidential Information. Recipient acknowledges that all of the Confidential
Information is owned solely by the Company (or its licensors) and that the unauthorized disclosure or use of such Confidential Information would cause irreparable harm and significant injury, the degree of which may be difficult to ascertain.
Therefore, in the event of any breach of this Agreement, the Company is entitled to seek all forms of equitable relief (including an injunction and order for specific performance), in addition to all other remedies available at law or in equity.

 7.    Recipient and Representative Compliance with Securities Laws. Recipient agrees that the Confidential
Information is given in confidence in accordance with the terms of this Agreement, and Recipient will not take any action relating to the securities of the Company which would constitute insider trading, market manipulation, or any other violation
of applicable securities law. Recipient agrees to instruct all of its Representatives to whom it discloses Confidential Information that they may not take any action relating to the securities of the Company which would constitute insider trading,
market manipulation, or any other violation of applicable securities law. 
 8.    Joint and Several Obligations.
The Parties agree that the obligations of Observer and each of the Starwood Companies under this Agreement are joint and several. 

9.    Indemnity. 

(a)    The Company will indemnify and hold harmless Observer from and against any losses, claims, damages, liabilities and
expenses to which Observer may become subject, insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof) arise out of or are based upon Observer’s designation as a non-voting observer at meetings of the
Company’s Board of Directors and Committees thereof. The Company will reimburse Observer for such losses, claims, damages, liabilities and expenses as they are incurred, including for amounts incurred in connection with investigating or
defending any such loss, claim, damage, liability, expense or action. 
 (b)    Promptly after receipt by Observer under
Section 9(a) of notice of the commencement of any action (but in no event in excess of 30 days after receipt of actual notice), Observer will, if a claim in respect thereof is to be made against Observer under this Section 9, notify the
Company in writing of the commencement thereof, and the omission so to notify the Company will relieve the Company from any liability under this Section 9 as to the particular item for which indemnification is then being sought, but not from
any other liability which it may have to Observer. In case any such action is brought against Observer, and Observer notifies the Company of the commencement thereof, the Company will be entitled, to the extent it may wish, to participate in the
defense thereof, with separate counsel. Such participation shall not relieve the Company of the obligation to reimburse Observer for reasonable legal and other expenses (subject to Subsection (c)) incurred by Observer in defending itself, except for
such expenses incurred after the Company has deposited funds sufficient to effect the settlement (unless an expungement proceeding has been initiated), with prejudice, of the claim in respect of which indemnity is

 
sought. The Company shall not be liable to Observer on account of any settlement of any claim or action effected without the consent of the Company, such consent not to be unreasonably withheld
or delayed. 
 (c) The Company shall pay all reasonable legal fees and expenses of Observer in the defense of such claims or actions;
provided, however, that the Company shall not be obliged to pay legal expenses and fees to more than one law firm (in addition to local counsel) in connection with the defense of similar claims arising out of the same alleged acts or omissions
giving rise to such claims notwithstanding that such actions or claims are alleged or brought by one or more parties against Observer. Such law firm (in addition to local counsel) shall be paid only to the extent of services performed by such law
firm and no reimbursement shall be payable to such law firm on account of legal services performed by another law firm (other than local counsel). 

10.    Insurance. For the duration of Observer’s appointment as Observer of the Company, the Company shall
cause to be maintained in effect a policy of liability insurance coverage (if available) for Observer against liability that may be asserted against or incurred by him in his capacity as Observer which is substantially comparable in scope and amount
to that provided by the Company’s current policies of directors’ and officer’s liability insurance. Upon reasonable request, the Company shall provide Observer or his counsel with a copy of all directors’ liability insurance
applications, binders, policies, declarations, endorsements, and other related materials. Notwithstanding the foregoing, the Company may, but shall not be required to, create a trust fund, grant a security interest, or use other means, including,
without limitation, a letter of credit, to ensure the payment of such amounts as may be necessary to satisfy its obligations to indemnify and advance expenses pursuant to this Agreement. 

11.    Governing Law: Venue for Disputes. This Agreement shall be governed in all respects by the laws of the State
of Maryland (without giving effect to principles of conflicts of laws which would lead to the application of the laws of another jurisdiction). Each party hereby irrevocably and unconditionally consents to the jurisdiction of the federal and state
courts in Los Angeles County, State of California, for any action, suit or proceeding arising out of or related to this Agreement. Each party hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any action,
suit or proceeding arising out of or relating to this Agreement in the federal and state courts in Los Angeles County, State of California, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court
that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 

12.    Notices. All notices and communications hereunder shall be in writing and shall be deemed to have been given
and delivered when deposited in the United States mail, postage prepaid, registered or certified mail, to the applicable address set forth below. 
  

			
	To the Company:	 	Griffin Capital Essential Asset REIT, Inc.
		 	Attention: Kevin A. Shields
		 	2121 Rosecrans Avenue, Suite 3321
		 	El Segundo, California 90245
		 	Fax: (310) 606-5910
		 	
	To Observer:	 	Warren DeHaan
		 	c/o Starwood Property Trust, Inc.
		 	591 West Putnam Avenue
		 	Greenwich, Connecticut 06830
		 	
	To the Starwood Companies:	 	Starwood Property Trust, Inc.
		 	SPT Griffin Holdings, LLC

  
  
  

 
  
  

 
  
  

 

			
		 	591 West Putnam Avenue
		 	Greenwich, Connecticut 06830
		 	Attention: Andrew Sossen

  
 13.    Entire
Agreement. This Agreement, together with the Investor Rights Agreement, constitutes the complete and exclusive statement regarding the subject matter of this Agreement and supersedes all prior agreements, understandings and communications, oral
or written, between the parties regarding the subject matter of this Agreement. 
 14.    Expenses. The Company
agrees to reimburse the Observer and the Starwood Companies, and the Starwood Companies agree to reimburse the Company, for the actual and reasonable costs and expenses of the other party that such other party incurs in connection with the
enforcement of this Agreement or any claim, damages or litigation relating to any breach of this Agreement, if such other party is found to have breached this Agreement. 

15.    Term. The provisions of Section 1 hereof shall terminate and be of no further force or effect pursuant
to Section 1(e) hereof. Notwithstanding the provisions of this Section 15, the provisions of Sections 2, 3, 4, 6, 7, 8, 9,11, 14 and this Section 15 shall survive any termination or expiration of this Agreement. 

[SIGNATURES APPEAR ON NEXT PAGE] 

 IN WITNESS WHEREOF, the undersigned have hereto executed this Agreement as of the date first
above written. 
  

									
		 		 	GRIFFIN CAPITAL ESSENTIAL ASSET REIT, INC.
				
		 		 	By:	 	/s/ Kevin A. Shields
		 		 	Name:	 		 	Kevin A. Shields
		 		 	Title:	 	Chief Executive Officer
			
		 		 	OBSERVER:
			
		 		 	/s/ Warren DeHaan
		 		 	Name:	 	Warren DeHaan
			
		 		 	SPT GRIFFIN HOLDINGS, LLC
				
		 		 	By:	 	/s/ Andrew J. Sossen
		 		 	Name:	 	Andrew J. Sossen
		 		 	Title:	 	Authorized Signature
			
		 		 	STARWOOD PROPERTY TRUST, INC.
				
		 		 	By:	 	/s/ Andrew J. Sossen
		 		 	Name:	 	Andrew J. Sossen
		 		 	Title:	 	Authorized SignatureEX-10.1

 Exhibit 10.1 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 EXCLUSIVE 

LICENSE AGREEMENT 
 Between

 THE REGENTS OF THE 

UNIVERSITY OF CALIFORNIA 

And 
 MEDIVATION, INC. 

and 
 MEDIVATION PROSTATE
THERAPEUTICS, INC. 
 “[ * ]” 

(UC Case No. [ * ]) 
 and 

“[ * ]” 
 (UC Case No. [ *
]) 

  
 1. 

 LICENSE AGREEMENT 

TABLE OF CONTENTS 
  

							
	ARTICLE	  	PAGE NUMBER	 
		
	RECITALS	  	 	3	  
			
	 1.
	 	DEFINITIONS	  	 	4	  
	 2.
	 	GRANT	  	 	6	  
	 3.
	 	SUBLICENSES	  	 	6	  
	 4.
	 	FEES	  	 	7	  
	 5.
	 	ROYALTIES	  	 	8	  
	 6.
	 	DILIGENCE	  	 	9	  
	 7.
	 	PATENT FILING, PROSECUTION AND MAINTENANCE	  	 	10	  
	 8.
	 	PATENT INFRINGEMENT	  	 	11	  
	 9.
	 	PROGRESS AND ROYALTY REPORTS	  	 	12	  
	 10.
	 	BOOKS AND RECORDS	  	 	12	  
	 11.
	 	LIFE OF THE AGREEMENT	  	 	12	  
	 12.
	 	TERMINATION BY THE REGENTS	  	 	13	  
	 13.
	 	TERMINATION BY LICENSEE	  	 	13	  
	 14.
	 	DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION	  	 	13	  
	 15.
	 	PATENT MARKING	  	 	14	  
	 16.
	 	USE OF NAMES AND TRADEMARKS	  	 	14	  
	 17.
	 	LIMITED WARRANTY	  	 	14	  
	 18.
	 	INDEMNIFICATION	  	 	15	  
	 19.
	 	NOTICES	  	 	16	  
	 20.
	 	ASSIGNABILITY	  	 	17	  
	 21.
	 	LATE PAYMENTS	  	 	17	  
	 22.
	 	WAIVER	  	 	17	  
	 23.
	 	FAILURE TO PERFORM	  	 	17	  
	 24.
	 	GOVERNING LAW	  	 	17	  
	 25.
	 	GOVERNMENT APPROVAL OR REGISTRATION	  	 	17	  
	 26.
	 	EXPORT CONTROL LAWS	  	 	17	  
	 27.
	 	PREFERENCE FOR UNITED STATES INDUSTRY	  	 	17	  
	 28.
	 	FORCE MAJEURE	  	 	18	  
	 29.
	 	CONFIDENTIALITY	  	 	18	  
	 30.
	 	HHMI THIRD-PARTY BENEFICIARY STATUS	  	 	19	  
	 31.
	 	MISCELLANEOUS	  	 	19	  
		
	APPENDIX A	  	 	21	  

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2. 

 EXCLUSIVE LICENSE AGREEMENT 

This Agreement is made and is effective this 12th day of August 2005, (the “Effective Date”) between THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA (“The Regents”), a California corporation having its corporate offices located at 1111 Franklin Street, Oakland, California 94607-5200, acting through its offices located at 10920 Wilshire Blvd, Suite 1200, Los Angeles,
California 90024-1406, and MEDIVATION, INC. (“Medivation”), a Delaware corporation, and MEDIVATION PROSTATE THERAPEUTICS, INC. (“MPT”) (Medivation and MPT together “Licensee”), a Delaware
corporation and wholly-owned subsidiary of Medivation, each having a principal place of business at 501 Second Street, Suite 211, San Francisco, CA 94107. 

RECITALS 
 WHEREAS, certain inventions
(the “Inventions”), generally characterized as “[ * ]” (UC Case No. [ * ]) and “[ * ]” (UC Case No. [ * ]), was made in the course of research at the University of California, Los Angeles by [ * ], employee(s) of The
Regents, and [ * ], an employee of the Howard Hughes Medical Institute (“HHMI”) and member of the faculty of the University of California, Los Angeles, and is claimed in Regents’ Patent Rights as defined below; 

WHEREAS, each of [ * ], as employees of The Regents, is obligated to assign their right, title and interest in and to the Invention to The Regents; 

WHEREAS, HHMI assigned its rights in the Invention to The Regents under the terms of the interinstitutional agreement with HHMI having UC Control
No. 1986-18-0017 (“HHMI Interinstitutional Agreement”), and accordingly, The Regents has the authority to license the entire interest in the Invention and any patent rights claiming it; 

WHEREAS, under the terms of the HHMI Interinstitutional Agreement, HHMI has reserved nonexclusive, paid-up, royalty-free, irrevocable licenses, with no right
to sublicense others, to make and use the Invention for research purposes; 
 WHEREAS, the Invention was developed with United States Government funds, and
The Regents has elected title thereto and granted a royalty-free nonexclusive license to the United States Government on August 10, 2005, as required under 35 U.S.C. §201-212; 

WHEREAS, Licensee and The Regents entered into a secrecy agreement effective [ * ] and expiring on [ * ] (“Secrecy Agreement”) to allow Licensee to
evaluate its interest in the Inventions and, as a result of its evaluation, Licensee wishes to obtain certain rights from The Regents; 
 WHEREAS,
Medivation and The Regents entered into a Letter Agreement effective [ * ] in which The Regents agreed to negotiate exclusively with Medivation for a license to certain rights in the Inventions; 

WHEREAS, Licensee is a “small business concern” as defined in 15 U.S.C. §632; and 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3. 

 WHEREAS, The Regents wishes that Regents’ Patent Rights be developed and utilized to the fullest extent so
that the benefits can be enjoyed by the general public. 
 The parties agree as follows: 

1. DEFINITIONS 
  

	1.1	“Regents’ Patent Rights” means The Regents interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under
Paragraph 7.3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and
entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos. [ * ] and [ * ]). 

  

	1.2	“Licensed Product” means any article, composition, apparatus, substance, chemical, or any other material covered by the claims of Regents’ Patent Rights or whose manufacture, use or sale would
constitute an infringement of any claim within Regents’ Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold by or utilizing or practicing a Licensed Method. This
definition of Licensed Product also includes a service either used by Licensee, an Affiliate, or sublicensee or provided by Licensee, an Affiliate or sublicensee to its customers when such service requires the use of Licensed Product or performance
of Licensed Method. Additionally, for the avoidance of doubt, if such product is a component of a larger unit such as a kit, composition of matter or combination, such kit, composition of matter or combination is deemed to be the Licensed Product
for purposes of this definition. 

  

	1.3	“Licensed Method” means any process or method which is covered by the claims of Regents’ Patent Rights or whose use or practice would constitute an infringement of any claim within Regents’
Patent Rights. 

  

	1.4	The “Field of Use” means the treatment or prevention of disease using the compositions of matter with the chemical structures identified in Regents’ Patent Rights; provided, however, that The
Regents will retain the right to provide such compounds included within the subject technology to third parties for [ * ]. 

  

	1.5	“Affiliate” means any corporation or other business entity in which Licensee owns or controls, directly or indirectly, at least 50% of the outstanding stock or other voting rights entitled to elect
directors. In any country where the local law does not permit foreign equity participation of at least 50%, then “Affiliate” means any company in which Licensee owns or controls, directly or indirectly, the maximum percentage of
outstanding stock or voting rights that is permitted by local law. 

  

	1.6	“First Commercial Sale” means the first sale of any Licensed Product by Licensee or any Affiliate or Sublicensee, following approval of its marketing by the appropriate governmental agency for the
country in which the sale is to be made. When governmental approval is not required. “First Commercial Sale” means the first sale in that country. 

  

	1.7	“Final Sale” means any sale, transfer, lease, exchange or other disposition or provision of a Licensed Product and/or a Licensed Method to a Customer. A Final Sale shall be deemed to have occurred upon
the earliest to occur of the following (as applicable): (a) the transfer of title to such Licensed Product and/or Licensed Method to a Customer, (b) the shipment of such Licensed Product to a Customer, (c) the provision of a Licensed
Method to a Customer, (d) the provision of an invoice for such Licensed Product or Licensed Method to a Customer, or (e) payment by the Customer for Licensed Products or Licensed Methods. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 4. 

	1.8	“Net Sales” means the total of the gross amount invoiced or otherwise charged (whether consisting of cash or any other forms of consideration) for the Final Sale of Licensed Products or Licensed Methods
by Licensee, or by any Affiliate, Joint Venture or Sublicensee to Customers, less the following deductions (to the extent included in and not already deducted from the gross amount invoiced or otherwise charged) to the extent reasonable and
customary: cash, trade or quantity discounts actually granted to Customers; sales, use, tariff, import/export duties or other excise taxes imposed on particular sales (excepting value added taxes or income taxes); transportation charges, including
insurance to the extent actually paid by the Customer; and allowances or credits to Customers because of rejections or returns. Where Licensee or any Affiliate, Joint Venture or Sublicensee is the Customer, then Net Sales shall be based on the gross
amount normally invoiced or otherwise charged to other Customers in an arms length transaction for such Licensed Products or Licensed Methods. For the avoidance of doubt, if Licensee or any Affiliate, Joint Venture or Sublicensee supplies (directly
or indirectly) a product that constitutes a Licensed Product to any Affiliate, Joint Venture or Sublicensee and such Affiliate, Joint Venture or Sublicensee includes such product in another product, then Net Sales shall be based on the total gross
amount invoiced or otherwise charged for such other product in its entirety. 

  

	1.9	“Sublicensee” means any third party sublicensed by Licensee to make, have made, use, sell, offer for sale or import any Licensed Product or to practice any Licensed Method. 

 

	1.10	“Sublicensing Income” means income received by Licensee under or on account of Sublicenses. Sublicensing Income includes income received including but not limited to license issue fees, milestone
payments, and the like but specifically excludes royalties on the sale or distribution of Licensed Products or the practice of Licensed Methods. If Licensee accepts noncash consideration from its sublicensee, then, at the option of The Regents,
Licensee will compensate The Regents with the cash equivalent of such noncash consideration. Not included in the definition of Sublicensing Income is income received by Licensee as payment or reimbursement for research costs conducted by or for
Licensee, including costs associated with materials, equipment or clinical testing. 

  

	1.11	“Customer” means any individual or entity that receives Licensed Products or Licensed Methods, provided however, that Licensee or any Affiliate, Joint Venture or Sublicensee shall be deemed a Customer
only if it receives Licensed Products or Licensed Services for its own end-use and not resale. 

  

	1.12	“Sublicense” means any transaction (a) in which the Licensee grants to any third party a license to make, have made, use, sell, offer for sale or import any Licensed Product or to practice any Licensed
Method, and (b) which is not a Licensee Liquidity Transaction. 

  

	1.13	“Licensee Liquidity Transaction” means (a) the sale of all or substantially all of the business or assets of MPT, whether by merger, consolidation, asset acquisition, stock acquisition, or otherwise,
(b) any corporate partnership, joint venture or other such transaction between MPT and one or more non-Affiliate third parties which has as its purpose the research, development and/or commercialization of one or more Licensed Products or Licensed
Methods, and pursuant to which MPT retains significant ongoing financial and/or operational responsibility for such research, development and/or commercialization, (c) the initial public offering of MPT’s common stock, or (d) the receipt of
marketing approval for a Licensed Product in [ * ]. 

  

	1.14	“Licensee” means both Medivation, Inc. and Medivation Prostate Therapeutics, Inc., both of which shall be responsible for all obligations and duties under this Agreement. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 5. 

 2. GRANT 
  

	2.1	Subject to the limitations set forth in this Agreement, including the licenses granted to the United States Government and those reserved by HHMI set forth in the recitals and in Paragraph 2.2 and the rights reserved by
The Regents in Paragraph 2.3, The Regents hereby grants to Licensee an exclusive license (the “License”) under Regents’ Patent Rights, in jurisdictions where Regents’ Patent Rights exist, to make, have made, use, sell, offer for
sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law. 

  

	2.2     2.2a	The License is subject to all the applicable provisions of any license to the United States Government executed by The Regents and is subject to any overriding obligations to the United States Federal Government under
35 U.S.C. §200-212 and applicable governmental implementing regulations and the obligation to report on the utilization of the Invention set forth in 37 CFR §401.14(h). Moreover, the Licenses granted to Licensee hereunder also are subject
to the National Institutes of Health “Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources” set forth in 64F.R. 72090 (Dec. 23, 1999). 

 

	 	2.2b	The License granted hereunder is also subject to the paid-up, non-exclusive, irrevocable licenses reserved by HHMI to make and use the Invention for its research purposes. Such licenses reserved by HHMI specified in the
recitals and the immediately prior sentence do not include the right to sublicense others. Moreover, the Licenses granted to Licensee hereunder also are subject to HHMI’s statement of policy on research tools. Note: HHMI’s policy can be
found at www.hhmi.org/about/ogc/policies.html. 

  

	2.3	The Regents expressly reserves the right to use Regents’ Patent Rights and associated technology for educational, research and clinical purposes including publication of research results and sharing research
results with other non-profit institutions, and allowing other non-profit research institutions to use Regents’ Patent Rights and associated technology for the same purpose. 

3. SUBLICENSES 
  

	3.1	The Regents also grants to Licensee the right to issue exclusive or nonexclusive sublicenses to third parties to make, have made, use sell, offer for sale or import Licensed Products and to practice Licensed Methods in
any jurisdiction in which Licensee has exclusive rights under this Agreement (“Sublicenses”). All Sublicenses will include all of the rights of, and will require the performance of all the obligations due to, The Regents and HHMI (and, if
applicable, the United States Government) under this Agreement other than those rights and obligations specified in, Article 4 (Fees), Paragraph 5.2 (minimum annual royalties), and Paragraphs 7.1 and 7.2 (reimbursement of patent costs).

  

	3.2	Licensee must pay to The Regents (a) [ * ] of all Sublicensing Income from all Sublicenses granted prior to [ * ]; (b) [ * ] of all Sublicensing Income from all Sublicenses granted after [ * ] but prior to [ *
]; and (c) ten percent (10%) of all Sublicensing Income from all Sublicenses granted thereafter. If, as part of the same or a related transaction in which Licensee sublicenses Regents’ Patent Rights to a third party, Licensee also
licenses other patent rights to such third party, Licensee and The Regents shall make a good faith determination in apportioning the value of Sublicensing Income as to the total consideration received from such third party. 

 

	3.3	On Net Sales of Licensed Products sold or disposed of by a Sublicensee, Licensee must pay to The Regents an earned royalty in accordance with Article 5 (Royalties) as if these were Licensee’s Net Sales. Any
royalties received by Licensee in excess of royalties due to The Regents under this Paragraph 3.3 belong to Licensee. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 6. 

	3.4	Licensee must provide to The Regents a copy of each Sublicense within [ * ] of execution, and a copy of all information submitted to Licensee by Sublicensees relevant to the computation of the payments due to The
Regents under this Article 3. 

  

	3.5	If this Agreement is terminated for any reason, all outstanding Sublicenses, not in default, will be assigned by Licensee to The Regents, [ * ]. The Sublicenses will [ * ] with [ * ], but [ * ], and [ * ], including [ *
]. [ * ]. 

 4. FEES 
  

	4.1	In partial consideration for the License, Licensee will pay to The Regents a license issue fee of fifteen thousand dollars ($15,000,000) within [ * ] of the Effective Date. This fee is nonrefundable and is not an
advance against royalties. 

  

	4.2     4.2a	Within [ * ] of the Effective Date, Licensee will grant to The Regents options to purchase 150,000 shares of Common Stock of Licensee. All options issued to The Regents will be [ * ] upon [ * ], at no cost to The
Regents, and become exercisable immediately prior to the closing of the first Licensee Liquidation Transaction. 

  

	 	4.2b	The Regents’ acceptance of equity is contingent upon receiving approval from the University of California Office of the President, and if such approval is not granted, the parties will negotiate an alternate form
of financial consideration in lieu of the equity component due The Regents. 

  

	 	4.2c	Licensee’s shareholder purchase agreement, stock restriction agreement, or derivatives thereof, shall contain language that permits The Regents to distribute, under The Regents’ Patent Policy, a share of the
options to its inventors of Regents Patent Rights licensed hereunder. 

  

	 	4.2d	Licensee will be responsible for funding all costs associated with the development and commercialization of Regents’ Patent Rights, to the extent licensed hereunder, including without limitation all patent
prosecution and maintenance costs. Medivation will provide capital contributions to MPT to finance such costs, and will be entitled to receive one share of MPT’s Common Stock for each one dollar ($1.00) of capital contributions made to MPT.
Capital contributions may include both direct infusions of cash from Medivation to MPT, and reasonable allocations to MPT of Medivation’s costs. 

  

	 	4.2e	The parties acknowledge that Medivation’s business strategy is to operate as a publicly traded holding company, with multiple operating subsidiaries. As such, Medivation will be entitled to allocate all of its
costs to its various operating subsidiaries, including MPT. All costs directly attributable to activities performed on behalf of a specific operating subsidiary, such as patent prosecution, maintenance and enforcement costs, compound manufacturing
costs, preclinical and clinical testing costs, etc., will be allocated exclusively to the applicable subsidiary. All other costs, including management, facilities, insurance, compliance, etc., will be allocated to Medivation’s operating
subsidiaries, including MPT, equally or on any other basis Medivation deems to be fair in its reasonable discretion. 

  

	 	4.2f	Medivation will maintain complete and accurate financial records of its and MPT’s operations, including capital contributions from Medivation and allocations of Medivation’s costs, and these records will be
open to review by The Regents and its professional advisers on commercially reasonable terms, subject to the confidentiality provisions of Article 29 (Confidentiality). 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 7. 

	4.3	For each Licensed Product reaching the milestones indicated below, Licensee must make the following payments to The Regents within [ * ] of reaching the milestones: 

 

	 	4.3a	$[ * ] upon [ * ] of a Licensed Product; $[ * ] upon [ * ] of a Licensed Product [ * ]; maximum total milestones under 4.3a of $[ * ]; 

 

	 	4.3b	$[ * ] upon [ * ] of a Licensed Product; $[ * ] upon [ * ] of a Licensed Product [ * ]; maximum total milestones under 4.3b of $[ * ]. 

 

	 	4.3c	$[ * ] upon [ * ] of a Licensed Product; $[ * ] upon [ * ] of a Licensed Product [ * ]; maximum total milestones under 4.3c of $[ * ]. 

 

	 	4.3d	$2,000,000 upon receipt of approval to market a Licensed Product in the U.S. or in the major EU countries (UK, FR, IT, GE, SP); $[ * ] upon [ * ] Licensed Product [ * ]; maximum total milestones under 4.3d of $[ * ].

  

	 	4.3e	The Regents may elect, at their sole option, to receive in the form of additional options, in lieu of cash, any milestone payments earned prior to [ * ] (as defined in Paragraph 4.2a). If The Regents elect to take any
such milestone payment(s) in the form of options, the options will be [ * ] upon [ * ], at no cost to The Regents, become exercisable immediately prior to [ * ], and will be valued at [ * ]. Milestone payments earned after [ * ] will be payable
solely in cash. 

  

	4.4	Licensee must pay to The Regents a license maintenance fee of [ * ] dollars ($[ * ]) beginning on the [ * ] anniversary date of the Effective Date of this Agreement and continuing annually on each anniversary date of
the Effective Date. The maintenance fee will not be due and payable on any anniversary date of the Effective Date if on that date Licensee is commercially selling a Licensed Product and paying an earned royalty to The Regents on the sales of that
Licensed Product. The license maintenance fees are non-refundable and are not an advance against royalties. 

 5. ROYALTIES

  

	5.1	Licensee must pay to The Regents for sales by Licensee or its Affiliates an earned royalty of four (4) % of Net Sales of Licensed Products or Licensed Methods. 

 

	5.2	Licensee must pay to The Regents a minimum annual royalty of [ * ] dollars ($[ * ]) for the life of Regents’ Patent Rights, beginning in the year of the First Commercial Sale of Licensed Product. Licensee must pay
the minimum annual royalty to The Regents by [ * ] of each year. The minimum annual royalty will be credited against the earned royalty due and owing for the calendar year in which the minimum payment was made. 

 

	5.3	Paragraphs 1.1, 1.2, 1.3 and 1.4 define Regents’ Patent Rights, Licensed Product, Licensed Method and the Field of Use so that royalties are payable on products covered by pending patent applications and issued
patents. Royalties accrue for the duration of this Agreement. 

  

	5.4	Licensee must pay royalties owed to The Regents on a [ * ] basis. Licensee must pay the royalties within [ * ] of the end of the calendar [ * ] in which the royalties accrued. 

 

	5.5	All monies due The Regents must be paid in United States funds. When Licensed Products are sold for monies other than United States dollars, the royalties will first be determined in the foreign currency of the country
in which those Licensed Products were sold and, second, converted into equivalent United States funds. Licensee must use the exchange rate established by the Bank of America in San Francisco, California on the last day of the calendar quarter.

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 8. 

	5.6	Any tax for the account of The Regents required to be withheld by Licensee under the laws of any foreign country must be promptly paid by Licensee for and on behalf of The Regents to the appropriate governmental
authority. Licensee will use its best efforts to furnish The Regents with proof of payment of any tax. Licensee is responsible for all hank transfer charges. All payments made by Licensee in fulfillment of The Regents’ tax liability in any
particular country will be credited against fees or royalties due The Regents for that country. 

  

	5.7	If at any time legal restrictions prevent the acquisition or prompt remittance of United States Dollars by Licensee with respect to any country where a Licensed Product is sold, the Licensee shall pay royalties due to
The Regents [ * ]. 

  

	5.8	If any patent or any claim included in Regents’ Patent Rights is held invalid or unenforceable in a final decision by a court of competent jurisdiction from which no appeal has or can be taken, all obligation to
pay royalties based on that patent or claim or any claim patentably indistinct from it will cease as of the date of that final decision. Licensee will not, however, be relieved from paying any royalties that accrued before that decision or that is
based on another patent or claim not involved in that decision. 

  

	5.9	No royalties will be collected or paid on Licensed Products sold to the United States Federal Government, or any agency of the United States Government. The Licensee and its Sublicensee will reduce the amount charged
for Licensed Products distributed to the United States Government by the amount of the royalty. 

 6. DILIGENCE 

 

	6.1	Upon the execution of this Agreement, Licensee must diligently proceed with the development, manufacture and sale (“Commercialization”) of Licensed Products and must earnestly and diligently endeavor to market
them within a reasonable time after execution of this Agreement and in quantities sufficient to meet the market demands for them. 

  

	6.2	Licensee must endeavor to obtain all necessary governmental approvals for the Commercialization of Licensed Products. 

  

	6.3	Subject to Licensee’s rights under Paragraph 6.6, The Regents has the right and option to either terminate this Agreement or reduce Licensee’s exclusive license to a nonexclusive license if Licensee fails to
perform any of the terms in this Paragraph 6.3. This right, if exercised by The Regents, supersedes the rights granted in Article 2 (Grant). 

  

	 	6.3a	[ * ] a Licensed Product [ * ] by the [ * ] anniversary of the date of this Agreement; 

  

	 	6.3b	[ * ] of a Licensed Product by the [ * ] anniversary of the date of this Agreement; 

  

	 	6.3c	[ * ] of a Licensed Product by the [ * ] anniversary of the date of this Agreement; 

  

	 	6.3d	[ * ] a Licensed Product [ * ] by the [ * ] anniversary of the date of this Agreement; and 

  

	 	6.3e	[ * ] of a Licensed Product by the [ * ] anniversary of the date of this Agreement. 

  

	6.4	Licensee has the sole discretion for making all decisions as to how to commercialize any Licensed Product. 

  

	6.5	 As further evidence of its due diligence in Commercialization of Licensed Products, Licensee represents and warrants that it has cash of at least [ *
] dollars ($[ * ]), and, Licensee further agrees 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 9. 

	 	
that it will spend no less than [ * ] dollars ($[ * ]) per year on the Commercialization of Licensed Products. If Licensee breaches this Paragraph 6.5, and subject to Licensee’s rights under
Paragraph 6.6, The Regents has the right and option to either terminate this Agreement or reduce Licensee’s exclusive license to a nonexclusive license. This right, if exercised by The Regents, supersedes the rights granted in Article 2
(Grant). 

  

	6.6	In the event that The Regents wishes to exercise its right to terminate this Agreement, or to reduce Licensee’s exclusive license to a nonexclusive license, pursuant to Paragraph 6.3 or Paragraph 6.5 above, then in
any such case The Regents will deliver to Licensee a written notice of the action The Regents wishes to take and the basis therefor (a “Termination Notice”). Upon receipt of any Termination Notice, and for a period of [ * ] thereafter,
Licensee shall have a [ * ] right to suspend the action proposed to be taken by The Regents in the Termination Notice for a period of [ * ] by payment to The Regents of [ * ] dollars ($[ * ]) in cash. If Licensee has not made payment to The Regents
by the end of such [ * ] period, then the action specified in the Termination Notice shall take effect on such [ * ] day. If Licensee makes the payment, then (a) each milestone date in Paragraph 6.3 shall be extended by [ * ] year, and
(b) Licensee shall have [ * ] to bring itself into compliance with the spending requirements in Paragraph 6.5. 

 7.
PATENT FILING, PROSECUTION AND MAINTENANCE 
  

	7.1	As long as Licensee is current in reimbursing patent prosecution costs, The Regents will file, prosecute and maintain the patents and applications comprising Regents’ Patent Rights. These patents will be held in
the name of The Regents and will be obtained with counsel of The Regents’ choice. The Regents must provide Licensee with copies of each patent application, office action, response to office action, request for terminal disclaimer, and request
for reissue or reexamination of any patent or patent application under Regents’ Patent Rights. The Regents will consider any comments or suggestions by Licensee. The Regents is entitled to take action to preserve rights or minimize costs
whether or not Licensee has commented. 

  

	7.2	Licensee will bear all costs incurred prior to and during the term of this Agreement in the preparation, filing, prosecution and maintenance of patent applications and patents in Regents’ Patent Rights. Prosecution
includes interferences, oppositions and any other inter partes matters originating in a patent office. Licensee must send payment to The Regents within [ * ] of Licensee’s receipt of an invoice. 

 

	7.3	Licensee has the right to request patent protection on the Invention in foreign countries if the rights are available. Licensee must notify The Regents of its decision within [ * ] of the filing of the corresponding
United States patent application. This notice must be in writing and must identify the countries desired. The absence of this notice from Licensee to The Regents will be considered an election not to secure foreign rights. 

 

	7.4	[ * ] after the filing of the corresponding United States application, but not sooner, The Regents will have the right to file patent applications at its own expense in any country which Licensee has not identified in
written notice provided by 7.3. These applications and resulting patents will not he subject to this Agreement. 

  

	7.5	Licensee’s obligation to underwrite and to pay all United States and foreign patent costs will continue for as long as this Agreement remains in effect. Licensee may terminate its obligations with respect to any
given patent application or patent upon [ * ] written notice to The Regents. The Regents will use its best efforts to curtail patent costs chargeable to Licensee under this Agreement after this notice is received from Licensee. The Regents may
continue prosecution or maintenance of these application(s) or patent(s) at its sole discretion and expense, and Licensee will have no further rights or licenses to them. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 10. 

	7.6	The Regents will use its best efforts to not allow any Regents’ Patent Rights for which Licensee is licensed and is underwriting the costs of to lapse or become abandoned without Licensee’s authorization or
reasonable notice, except for the filing of continuations, divisionals, or the like which substitute for the lapsed application. 

8. PATENT INFRINGEMENT 
  

	8.1	In the event that The Regents (to the extent of the actual knowledge of the licensing professional responsible for the administration of this Agreement) or the Licensee learns of infringement of potential commercial
significance of any patent licensed under this Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence of such infringement available to it (the “Infringement
Notice”). During the period in which, and in the jurisdiction where, the Licensee has exclusive rights under this Agreement, neither The Regents nor the Licensee will [ * ] or [ * ] without first obtaining consent of the other. If [ *
] without first obtaining the written consent of [ * ] and if [ * ], then [ * ] to [ * ] under [ * ] will [ * ] without the [ * ] to provide [ * ]. Both The Regents and the Licensee will use their diligent efforts to cooperate with each other to
terminate such infringement without litigation. 

  

	8.2	If infringing activity of potential commercial significance by the infringer has not been abated within [ * ] following the date the infringement Notice takes effect, then the Licensee may institute suit for patent
infringement against the infringer. The Regents may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of the Licensee’s suit or any
judgment rendered in the suit. The Licensee may not join The Regents in a suit initiated by Licensee without [ * ]. If, in a suit initiated by the Licensee, The Regents is involuntarily joined other than by the Licensee, then the Licensee will pay
any costs incurred by The Regents arising out of such suit, including but not limited to, any legal fees of counsel that The Regents selects and retains to represent it in the suit. 

 

	8.3	If, within [ * ] days following the date the Infringement Notice takes effect, infringing activity of potential commercial significance by the infringer has not been abated and if the Licensee has not brought suit
against the infringer, then The Regents may institute such suit for patent infringement against the infringer. If The Regents institutes such suit, then the Licensee may not join such suit without The Regents consent and may not thereafter commence
suit against the infringer for acts of infringement that are subject to The Regents suit or any judgment rendered in that suit. 

  

	8.4	Any recovery or settlement received in connection with any suit will first be shared by The Regents and the Licensee equally to cover any litigation costs each incurred and next shall be paid to The Regents or the
Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other. In any suit initiated by the Licensee, any recovery in excess of litigation costs will be shared between Licensee and The Regents as follows: [ * ].
In any suit initiated by The Regents, any recovery in excess of litigation costs will [ * ]. The Regents and the Licensee agree to be bound by all determinations of patent infringement, validity and enforceability but no other issue) resolved by any
adjudicated judgment in a suit brought in compliance with this Article 8 (Patent Infringement). 

  

	8.5	Any agreement made by the Licensee for purposes of settling litigation or other dispute shall comply with the requirements of Article 3 (Sublicenses) of this Agreement. 

 

	8.6	Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties).

  

	8.7	Any litigation proceedings will be controlled by the party bringing the suit, except that The Regents may be represented by counsel of its choice in any suit brought by the Licensee. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 11. 

 9. PROGRESS AND ROYALTY REPORTS 

 

	9.1	Beginning [ * ], Licensee must submit to The Regents [ * ] progress reports covering Licensee’s activities related to the development and testing of all Licensed Products and the obtaining of the governmental
approvals necessary for marketing. These progress reports must be made for each Licensed Product until its First Commercial Sale. 

  

	9.2	The progress reports submitted under Paragraph 9.1 must include the following topics: 

  

	 	9.2a	Summary of work completed. 

	 	9.2b	Key scientific discoveries. 

	 	9.2c	Summary of work in progress. 

	 	9.2d	Current schedule of anticipated events or milestones. 

	 	9.2e	Market plans for introduction of Licensed Products. 

	 	9.2f	A summary of resources (dollar value) spent in the reporting period. 

  

	9.3	Licensee must notify The Regents if Licensee or any of its Sublicensees or Affiliates ceases to be a small entity (as defined by the United States Patent and Trademark Office) under the provisions of 35 U.S.C.
§41(h). 

  

	9.4	Licensee must report the date of the First Commercial Sale in the royalty report immediately following that Sale. 

  

	9.5	After the First Commercial Sale of each Licensed Product, Licensee must make [ * ] royalty reports to The Regents by [ * ] of each year (i.e., within [ * ] from the end of each calendar [ * ]). Each royalty report must
cover Licensee’s most recently completed calendar [ * ] and must show: 

  

	 	9.5a	Gross sales and Net Sales of any Licensed Product. 

	 	9.5b	Number of each type of Licensed. Product sold. 

	 	9.5c	Royalties payable to The Regents. 

  

	9.6	Licensee must state in its royalty report if it had no sales of any Licensed Product. 

 10.
BOOKS AND RECORDS 
  

	10.1	Licensee must keep accurate books and records of all Licensed Products manufactured, used or sold. Licensee must preserve these books and records for at least [ * ] years from the date of the royalty payment to which
they pertain. 

  

	10.2	The Regents’ representatives or agents are entitled to inspect these books and records at reasonable times. The Regents will pay the fees and expenses of these inspections. If an error favoring Licensee of more
than [ * ]% of the total annual royalties is discovered, then Licensee will pay the fees and expenses of these inspections. 

11. LIFE OF THE AGREEMENT 
  

	11.1	Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement is in force from the Effective Date recited on page one and remains in effect for
the life of the last-to-expire patent in Regents’ Patent Rights, or until the last patent application licensed under this Agreement is abandoned and no patent in Regents’ Patent Rights ever issues. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 12. 

	11.2	Upon termination of this Agreement, Licensee will have no further right to make, have made, use or sell any Licensed Product except as provided in Article 14 (Disposition of Licensed Products on Hand. Upon Termination).

  

	11.3	Any expiration or termination of this Agreement will not affect the rights and obligations set forth in the following Articles: 

  

			
	Article 1	  	Definitions
	Article 4	  	Fees (Paragraph 4.1 only — license issue fee)
	Article 5	  	Royalties (except Paragraph 5.2)
	Article 7	  	Patent Filing, Prosecution and Maintenance (Paragraphs 7.2 and 7.5 only)
	Article 10	  	Books and Records
	Article 11	  	Life of the Agreement
	Article 14	  	Disposition of Licensed Products on Hand upon Termination
	Article 16	  	Use of Names and Trademarks
	Article 17	  	Limited Warranty
	Article 18	  	Indemnification
	Article 19	  	Notices
	Article 21	  	Late Payments
	Article 23	  	Failure to Perform
	Article 24	  	Governing Law
	Article 29	  	Confidentiality
	Article 30	  	HHMI Third Party Beneficiary Status

 12. TERMINATION BY THE REGENTS 

 

	12.1	If Licensee violates or fails to perform any material term or covenant of this Agreement, then The Regents may give written notice of the default (“Notice of Default”) to Licensee. If Licensee does not repair
the default within [ * ] after the effective date of the Notice of Default, then The Regents has the right to terminate this Agreement and the License by a second written notice (“Notice of Termination”) to Licensee. If The Regents sends a
Notice of Termination to Licensee, then this Agreement automatically terminates on the effective date of this notice. Termination does not relieve Licensee of its obligation to pay any royalty or fees owing at the time of termination and does not
impair any accrued right of The Regents. 

 13. TERMINATION BY LICENSEE 

 

	13.1	Licensee has the right at any time to terminate this Agreement in whole or with respect to any portion of Regents’ Patent Rights by giving written notice to The Regents. This notice of termination will be subject
to Article 19 (Notices) and will be effective [ * ] after the effective date of the notice. 

  

	13.2	Any termination in accordance with Paragraph 13.1 does not relieve Licensee of any obligation or liability accrued prior to termination. Nor does termination rescind anything done by Licensee or any payments made to The
Regents prior to the effective date of termination. Termination does not affect in any manner any rights of The Regents arising under this Agreement prior to tee 

14. DISPOSITION OF LICENSED PRODUCTS 

ON HAND UPON TERMINATION 
  

	14.1	Upon termination of this Agreement, Licensee will have the right to dispose of all previously made or partially made Licensed Products, but no more, within a period of [ * ]. But Licensee must submit royalty reports on
the sale of these Licensed Products and must pay royalties at the rate and at the time provided in this Agreement. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 13. 

 15. PATENT MARKING 

 

	15.1	Licensee must mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. 

16. USE OF NAMES AND TRADEMARKS 
  

	16.1	Neither party is permitted to use any name, trade name, trademark or other designation of the other party or its employees (including contraction, abbreviation or simulation of any of the foregoing) in advertising,
publicity or other promotional activity. Unless required by law, Licensee is expressly prohibited from using the name “The Regents of the University of California” or the name of any campus of the University of California.

  

	16.2	Licensee may not use the name of HHMI or of any HHMI employee (including [ * ]) in a manner that reasonably could constitute an endorsement of a commercial product or service; but that use for other purposes, even if
commercially motivated, is permitted provided that (a) the use is limited to accurately reporting factual events or occurrences, and (b) any reference to the name of HHMI or any HHMI employees in press releases or similar materials
intended for public release is approved by HHMI in advance. 

 17. LIMITED WARRANTY 

 

	17.1	The Regents warrants that it has the lawful right to grant this license to Licensee. 

  

	17.2	This License and the associated Invention are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKE NO REPRESENTATION OR WARRANTY
THAT ANY LICENSED PRODUCT WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. 

  

	17.3	IN NO EVENT WILL THE REGENTS BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE INVENTION OR LICENSED PRODUCTS OR THE USE OR THE PRACTICE OF LICENSED
METHODS. 

  

	17.4	Nothing in this Agreement will be construed as: 

  

	 	17.4a	A warranty or representation by The Regents as to the validity or scope of any Regents’ Patent Rights. 

  

	 	17.4b	A warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of third parties. 

 

	 	17.4c	An obligation on The Regents to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 8 (Patent Infringement). 

 

	 	17.4d	Conferring by implication, estoppel or otherwise any license or rights under any patents of The Regents other than Regents’ Patent Rights as defined herein, regardless of whether such patents are dominant or
subordinate to Regents’ Patent Rights. 

  

	 	17.4e	An obligation on The Regents to furnish any know-how not provided in Regents’ Patent Rights. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 14. 

 18. INDEMNIFICATION 

 

	18.1	Licensee will, and will require its Sublicensees to, indemnify, hold harmless, and defend The Regents, the sponsors of the research that led to the Invention, and the inventors of any invention claimed in patents or
patent applications under Regents’ Patent Rights (including the Licensed Products and Licensed Methods contemplated hereunder) and their employers, and the officers, employees, and agents of any of the foregoing, against any and all claims,
suits, losses, damages, costs, fees, and expenses resulting from, or arising out of the exercise of this license or any sublicense. This indemnification will include, but will not be limited to, any product liability. If The Regents, in its sole
discretion, believes that there will be a conflict of interest or it will not otherwise be adequately represented by counsel chosen by Licensee to defend The Regents in accordance with this Paragraph 18.1, then The Regents may retain counsel of its
choice to represent it, and Licensee will pay all expenses for such representation. 

  

	18.2	HHMI and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”) will be indemnified, defended by counsel acceptable to HHMI, and held harmless by Licensee and its Sublicensees from
and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) based on, resulting from, arising
out of or otherwise relating to this Agreement or any sublicense agreement, or the exercise of this license or any sublicense, including without limitation any cause of action relating to product liability (collectively, “Claims”). The
previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee. For clarity, acts conducted under the
retained rights and licenses set forth in Paragraph 2.2 and 2.3 above are not subject to this indemnification obligation of Licensee or any Sublicensee. If HHMI, in its sole discretion, believes that there will be a conflict of interest or it will
not otherwise be adequately represented by counsel chosen by Licensee to defend the HHMI Indemnitiees in accordance with this Paragraph 18.2, then HHMI may retain counsel of its choice to represent the HHMI Indemnitees, and Licensee will pay all
expenses for such representation. 

  

	18.3	Licensee, at its sole cost and expense, must insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain the following insurance: 

 

	 	18.3a	Upon execution of this Agreement, Comprehensive or Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 

 

					
	 Each occurrence
	  	$	[ 	* ]. 
	 Products/completed operations aggregate
	  	 	[ 	* ]. 
	 Personal and advertising injury
	  	$	[ 	* ]. 
	 General aggregate (commercial form only)
	  	$	[ 	* ]. 

 If the above insurance is written on a claims-made form, it shall continue for [ * ] following termination or
expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement; and 
  

	 	18.3b	Prior to [ * ], Comprehensive or Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 

 

					
	 Each occurrence
	  	$	[ 	* ]. 
	 Products/completed operations aggregate
	  	$	[ 	* ]. 
	 Personal and advertising injury
	  	$	[ 	* ]. 
	 General aggregate (commercial form only)
	  	$	[ 	* ]. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 15. 

 If the above insurance is written on a claims-made form, it shall continue for [ * ] following
termination or expiration of this Agreement; and 
  

	 	18.3c	Worker’s Compensation as legally required in the jurisdiction in which Licensee is doing business. 

  

	18.4	Licensee expressly understands, however, that the coverages and limits in Paragraphs 18.3a and 18.3b do not in any way limit Licensee’s liability under this Article. Licensee must furnish The Regents with
certificates of insurance evidencing compliance with all requirements. Licensee’s insurance must: 

  

	 	18.4a	Provide for [ * ] ([ * ] for non-payment of premium) advance written notice to The Regents of any cancellation of insurance coverages; Licensee will promptly notify The Regents of any material modification of the
insurance coverages. 

  

	 	18.4b	Indicate that The Regents of the University of California and HHMI have been endorsed as additional insureds under the coverages listed in Paragraph 18.3. 

 

	 	18.4c	Include a provision that the coverages will be primary and will not participate with, nor will be excess over, any valid and collective insurance or program of self-insurance carried or maintained by The Regents or

  

	18.5	The Regents will promptly notify Licensee in writing of any claim or suit brought against The Regents for which The Regents intends to invoke the provisions of this Article 18 (Indemnification). Licensee will keep The
Regents informed on a current basis of its defense of any claims pursuant to this Article 18 (Indemnification). In the case of an HHMI Indemnitee, notice shall be given reasonably promptly following actual receipt of written notice thereof by an
officer or attorney of HHMI. Notwithstanding the foregoing, the delay or failure of an HHMI Indemnitee to give prompt notice to Licensee of any Claim shall not affect the rights of such HHMI Indemnitee unless, and then only to the extent that, such
delay or failure is prejudicial to or otherwise adversely affects Licensee. Licensee will keep HHMI informed of its defense of any Claims pursuant to this Article 18 (Indemnification). 

19. NOTICES 
  

	19.1	Any notice or payment required to be given to either party must be sent to the respective address given below and is effective: (a) on the date of delivery if delivered in person, (b) five days after mailing
if mailed by first-class certified mail, postage paid, or (c) on the next business day if sent by overnight delivery. Either party may change its designated address by written notice. 

 

	 	For Licensee:	Medivation Prostate Therapeutics, Inc. 

	 	    	501 Second Street, Suite 211 

	 	    	San Francisco, CA 94107 

  

	 	    	Attention: Chief Financial Officer 

  

	 	For The Regents:	The Regents of the University of California 

	 	    	University of California, Los Angeles 

	 	    	Office of Intellectual Property Administration 

	 	    	10920 Wilshire Blvd., Suite 1200 

	 	    	Los Angeles, California 90095-1406 

  

	 	    	Attention: Director 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 16. 

 20. ASSIGNABILITY 

 

	20.1	This Agreement is binding upon and inures to the benefit of The Regents, its successors and assigns. But it is personal to Licensee and assignable by Licensee only with the written consent of The Regents. The consent of
The Regents will not be required if the assignment is in conjunction with the transfer of all or substantially all of the business of Licensee to which this license relates. 

21. LATE PAYMENTS 
  

	21.1	For each royalty payment or fee not received by The Regents when due, Licensee must pay to The Regents a simple interest charge of [ * ]% per annum to be calculated from the date payment was due until it was actually
received by The Regents. 

 22. WAIVER 
  

	22.1	The waiver of any breach of any term of this Agreement does not waive any other breach of that or any other term. 

23. FAILURE TO PERFORM 
  

	23.1	If either party takes legal action against the other because of a failure of performance due under this Agreement, then the prevailing party is entitled to reasonable attorney’s fees in addition to costs and
necessary disbursements. 

 24. GOVERNING LAW 
  

	24.1	THIS AGREEMENT IS TO BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and validity of any patent or patent application will be governed by the applicable laws of the
country of the patent or patent application. Any legal action brought by the parties hereto relating to this Agreement will be conducted in San Francisco, California. 

25. GOVERNMENT APPROVAL OR REGISTRATION 
  

	25.1	If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, Licensee will assume all legal obligations to do so. Licensee will
notify The Regents if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. Licensee will make all necessary filings and pay all costs including fees, penalties, and all other
out-of-pocket costs associated with such reporting or approval process. 

 26. EXPORT CONTROL LAWS 

 

	26.1	Licensee must observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and related technical data to foreign countries, including the International Traffic in Arms
Regulations (ITAR) and the Export Administration Regulations. 

 27. PREFERENCE FOR UNITED STATES INDUSTRY 

 

	27.1	Because this Agreement grants an exclusive right to a particular use of the Invention, Licensee must manufacture in the United States any products embodying this Invention or produced through the Invention’s use to
the extent required by 35 U.S.C. §201-212. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 17. 

 28. FORCE MAJEURE 

 

	28.1	The parties will be excused from any performance required under this Agreement if performance is impossible or unfeasible due to any catastrophe or other major event beyond their reasonable control, including war, riot,
or insurrection; lockouts or other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events abate, and in any event within one year, the parties’ respective obligations will resume. 

29. CONFIDENTIALITY 
  

	29.1	If either party discloses confidential infatuation to the other party, the disclosing party will designate this information as confidential by appropriate legend or instruction, and the receiving party will:

  

	 	29.1a	Use the same degree of care to maintain the secrecy of the confidential information as it uses to maintain the secrecy of its own information of like kind. 

 

	 	29.1b	Use the confidential information only to accomplish the purposes of this Agreement. 

 Subject to
the exclusions provided in Paragraphs 29.3 and 29.5, without limiting the generality of the foregoing, it is acknowledged and agreed that all progress and royalty reports delivered under Article 9 (Progress and Royalty Reports) constitute
confidential information of Licensee. 
  

	29.2	Neither party will disclose confidential information received from the other party except to its Board of Directors, employees, customers, distributors and other agents who are bound to it by similar obligations of
confidence. 

  

	29.3	Neither party will have any confidentiality obligation with respect to the confidential information belonging to or disclosed by the other party that: 

 

	 	29.3a	The receiving party can demonstrate by written records was previously known to it. 

  

	 	29.3b	The receiving party lawfully obtained from sources under no obligation of confidentiality. 

  

	 	29.3c	Is or becomes publicly available other than through an act or omission of the receiving party or any of its employees. 

  

	 	29.3d	Is required to be disclosed under the California Public Records Act, governmental audit or other requirement of law. 

  

	29.4	The provisions of this Article 29 will continue in effect for [ * ] after expiration or termination of this Agreement. 

  

	29.5	 Notwithstanding anything to the contrary contained in this Agreement, The Regents may release this Agreement or any Sublicense, including any terms
thereof, and information regarding royalty payments or other income received in connection with this Agreement to the inventors, senior administrative officials employed by The Regents, and individual Regents and to the senior administrative
officials employed by HHMI and individual trustees of HHMI upon their request. If such release is made, The Regents will request that such terms be kept in confidence in accordance with the provisions of this Article 29. If a third party inquires
whether a license to Regents’ Patent Rights is available, then The Regents may disclose the existence of this Agreement and the extent of the grant in Article 2 (Grant) to such third party, but will not disclose

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 18. 

 
the name of Licensee or any other terms or conditions of this Agreement, except where The Regents is required to release information under the California Public Records Act, a governmental audit
requirement, or other applicable law. 
 30. HHMI THIRD-PARTY BENEFICIARY STATUS 

 

	30.1	HHMI is not a party to this Agreement and has no liability to Licensee, any Sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of
its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

 31. MISCELLANEOUS 

 

	31.1	The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of, this Agreement. 

 

	31.2	This Agreement is not binding upon the parties until it has been signed below on behalf of each party, in which event it becomes effective as of the date recited on page one. 

 

	31.3	No amendment or modification of this Agreement will be valid or binding upon the parties unless made in writing and signed by each party. 

 

	31.4	This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter
hereof, except for the Secrecy Agreement dated [ * ] by and between The Regents and Licensee, which shall survive; provided, however, that in the case of any conflict between the provisions of the Secrecy Agreement and this Agreement, this Agreement
shall govern. 

  

	31.5	If any part of this Agreement is for any reason found to be unenforceable, all other parts nevertheless remain enforceable as long as a party’s rights under this Agreement are not materially affected. In lieu of
the unenforceable provision, the parties will substitute or add as part of this Agreement a provision that will be as similar as possible in economic and business objectives as was intended by the unenforceable provision. 

Both The Regents and Licensee have executed this Agreement in duplicate originals by their authorized officers on the dates written below: 

 

									
	MEDIVATION, INC.	  		  	 THE REGENTS OF THE UNIVERSITY

OF CALIFORNIA

					
	By	  	  /s/ C. Patrick Machado
	  		  	By	  	  /s/ Claire T. Wake

	Name	  	C. Patrick Machado	  		  	Name	  	Claire T. Wake
	Title	  	Senior Vice President and CFO	  		  	Title	  	Assistant Director
	Date	  	August 12, 2005	  		  	Date	  	August 15, 2005

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 19. 

			
	 MEDIVATION PROSTATE

THERAPEUTICS, INC.

		
	By	 	  /s/ C. Patrick Machado

	Name	 	C. Patrick Machado
	Title	 	Senior Vice President and CFO
	Date	 	August 12, 2005

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 20. 

 APPENDIX A 

REGENTS’ PATENT RIGHTS 

[ * ] 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 21. 

 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

UC Agreement Control No. 2006-04-0085 

This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by
and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware
corporation and subsidiary of Medivation (“MPT”). 
 WHEREAS, The Regents, Medivation and MPT are parties to
an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”); 
 WHEREAS,
The Regents, Medivation and MPT wish to strengthen the patent protection of certain members of the family of compounds covered in UC Case Nos. [ * ] and [ * ] by the filing of a patent application to cover additional [ * ] compounds, which are
disclosed in UC Case No [ * ] entitled “[ * ],” by [ * ], employees of The Regents, and [ * ], an employee of HHMI and a member of the faculty of the University of California, Los Angeles; 

WHEREAS, Medivation as the parent corporation of MPI will benefit directly from the agreements made herein; 

WHEREAS, the parties mutually intend to enter into this First Amendment to amend the terms of the Exclusive License Agreement, as specified
below. 
 THEREFORE, the parties hereby agree as follows: 
  

	1.	Paragraph 1.1 (“Regents’ Patent Rights”) is deleted and replaced with the following, which is amended to include “UC Case No. [ * ]” in the parenthetical at the end of the paragraph:

  

	 	1.1	“Regents’ Patent Rights” means The Regents interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under
Paragraph 7.3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and
entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos [ * ] and [ * ]). 

  

	2.	Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A attached to this First Amendment, which is amended to include the patent application to be filed under UC Case No. [ * ]

  

	3.	Paragraph 2.1 is deleted and replaced with the following, which is amended to delete “Licensee” and replace it with “MPT.” The effect of this Amendment is that MPT is the sole recipient of the
license granted pursuant to Paragraph 2.1. Notwithstanding this amendment, it is expressly understood that all other references to “Licensee” in the Exclusive License Agreement, including without limitation in Article 18 thereof
(Indemnification), shall refer to Medivation and MPT collectively. 

  

	 	2.1	Subject to the limitations set forth in this Agreement, including the licenses granted to the United States Government and those reserved by HHMI set forth in the recitals and in Paragraph 2.2 and the rights reserved by
The Regents in Paragraph 2.3, The Regents hereby grants to MPT an exclusive license (the “License”) under Regents’ Patent Rights, in jurisdictions where Regents’ Patent Rights exist, to make, have made, use, sell, offer for sale
and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 1. 

	4.	Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement shall remain unchanged and in full force and effect. 

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their authorized officers on the dates written below: 

 

									
	MEDIVATION, INC.	  		  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By	  	  /s/ C. Patrick Machado
	  		  	By	  	  /s/ Claire T. Wake

	Name	  	C. Patrick Machado	  		  	Name	  	Claire T. Wake, Ph.D.
	Title	  	Senior Vice President and CFO	  		  	Title	  	Assistant Director, Licensing
	Date	  	November 4, 2005	  		  	Date	  	November 4, 2005
				
	 MEDIVATION PROSTATE

THERAPEUTICS, INC.
	  		  		  	
					
	By	  	  /s/ C. Patrick Machado
	  		  		  	
	Name	  	C. Patrick Machado	  		  		  	
	Title	  	Senior Vice President and CFO	  		  		  	
	Date	  	November 4, 2005	  		  		  	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2. 

 APPENDIX A 

(First Amendment) 

REGENTS’ PATENT RIGHTS 

[ * ] 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3. 

 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

UC Agreement Control No. 2006-04-0085 

This Second Amendment to Exclusive License Agreement (“Second Amendment”), dated as of May 8, 2006, is made by and among The Regents of
the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of
Medivation (“MPT”). 
 WHEREAS, The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12,
2005 (the “Exclusive License Agreement”); 
 WHEREAS, Medivation has been supporting research in [ * ]’s laboratory at UCLA under a
Sponsored Research Agreement with an Effective Date of [ * ] (the “Sponsored Research Agreement”); 
 WHEREAS, an invention has been
developed at UCLA in the performance of the Sponsored Research Agreement, which is disclosed in UC Case No [ * ] entitled “[ * ],” by [ * ], employees of The Regents, [ * ], an employee of Howard Hughes Medical Institute
(“HHMI”) and a member of the faculty of the University of California, Los Angeles, and [ * ], an employee of HHMI; 
 WHEREAS, the
Sponsored Research Agreement grants Medivation the first right to negotiate for a license to inventions made by The Regents in the performance of the Sponsored Research Agreement, and Medivation has exercised its right and wishes to obtain an
exclusive license to the invention noted in the preceding WHEREAS clause; 
 WHEREAS, Medivation as the parent corporation of MPT will benefit directly from
the agreements made herein; and 
 WHEREAS, the parties mutually intend to enter into this Second Amendment to amend the terms of the Exclusive License
Agreement, as specified below. 
 THEREFORE, the parties hereby agree as follows: 
  

	1.	Paragraph 1.1 (“Regents’ Patent Rights”) is deleted and replaced with the following, which is amended to include “UC Case No. [ * ]” in the parenthetical at the end of the paragraph:

  

	 	1.1	“Regents’ Patent Rights” means The Regents interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under
Paragraph 7.3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and
entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos. [ * ] and [ * ]). 

  

	2.	Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A attached to this First Amendment, which is amended to include the patent application filed under UC Case No. [ * ]. 

 

	3.	In consideration for the addition of UC Case No. [ * ] to the Exclusive License Agreement, Medivation will pay to The Regents a fee of [ * ] dollars ($[ * ]) within [ * ] of the Effective Date of this Second Amendment.

  

	4.	Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement shall remain unchanged and in full force and effect. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 1. 

 The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their authorized officers
on the dates written below: 
  

									
	MEDIVATION, INC.	  		  	 THE REGENTS OF THE UNIVERSITY OF

CALIFORNIA

					
	By	  	  /s/ C. Patrick Machado
	  		  	By	 	  /s/ Claire T. Wake

	Name	  	C. Patrick Machado	  		  	Name	 	Claire T. Wake, Ph.D.
	Title	  	Senior Vice President and CFO	  		  	Title	 	Assistant Director, Licensing
	Date	  	May 8, 2006	  		  	Date	 	May 16, 2006
				
	MEDIVATION PROSTATE THERAPEUTICS, INC.	  		  		 	
					
	By	  	  /s/ C. Patrick Machado
	  		  		 	
	Name	  	C. Patrick Machado	  		  		 	
	Title	  	Senior Vice President and CFO	  		  		 	
	Date	  	May 8, 2006	  		  		 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2. 

 APPENDIX A 

(Second Amendment) 

REGENTS’ PATENT RIGHTS 

[ * ] 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3. 

 THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

UC Agreement Control No. 2006-04-0085 

This Third Amendment to Exclusive License Agreement (“Third Amendment”), dated as of June 12, 2006, is made by and among The
Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and
subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”). 
 BACKGROUND 

 

	A.	The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”), as amended on November 4, 2005 and May 8, 2006.

  

	B.	The Regents and MPT are parties to a Nonexclusive Bailment and License Agreement dated [ * ] (the “Nonexclusive Bailment”) that grants to MPT limited rights in a certain Field of Use to patent rights
generally characterized as “[ * ]” (UCLA Case No. [ * ]), which was made in the course of research at the University of California, Los Angeles by [ * ], employees of The Regents. MPT now wishes to obtain broader nonexclusive rights to
these patent rights in [ * ] and exclusive rights to these patent rights in certain countries and regions outside [ * ] in a different field of use. The Regents is willing to grant such rights. This Third Amendment is not intended to change the
scope of rights granted under the Nonexclusive Bailment. 

  

	C.	Medivation as the parent corporation of MPT will benefit directly from the agreements made herein. 

  

	D.	The parties mutually intend to enter into this Third Amendment to amend the terms of the Exclusive License Agreement, as specified below. 

THEREFORE, the parties hereby agree as follows: 
  

	1.	Paragraph 1.1 (“Regents’ Patent Rights”) is deleted and replaced with the following, which is amended to include “UC Case No. [ * ]” in the parenthetical at the end of the paragraph:

  

	 	1.1	“Regents’ Patent Rights” means The Regents’ interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under
Paragraph 7.3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and
entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos., [ * ] and [ * ]) 

  

	2.	Paragraph 2.1 is deleted and replaced with the following, which is amended to grant nonexclusive rights in the United States and exclusive rights outside the United States to the patent rights covered by UC Case No [ *
]: 

  

	 	2.1	Subject to the limitations set forth in this Agreement, including the licenses granted to the United States Government and those reserved by HHMI set forth in the recitals and in Paragraph 2.2 and the rights reserved by
The Regents in Paragraph 2.3, The Regents hereby grants to MPT an exclusive license (the “License”) under Regents’ Patent Rights, in jurisdictions where Regents’ Patent Rights exist, to make, have made, use, sell, offer
for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law; provided, however, that as to UC Case No. [ * ] only, the License shall be exclusive only in [ * ], and shall be non-exclusive
in [ * ]. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 1. 

	3.	Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A attached to this Third Amendment, which is amended to include the patent applications to be filed under UC Case No. [ * ] in [ * ] and
[ * ]. 

  

	4.	In consideration for the addition of the patent rights of UC Case No. [ * ] to the Exclusive License Agreement, Licensee will pay to The Regents a fee of [ * ] dollars ($[ * ]) within [ * ] of the Effective Date of this
Third Amendment. In addition, Licensee will pay a one-time milestone fee of [ * ] dollars ($[ * ]) upon [ * ] in [ * ] that would [ * ]. 

  

	5.	Article 7 (Patent Filing, Prosecution and Maintenance) is amended to include a new Paragraph 7.7: 

  

	 	7.7	Notwithstanding the foregoing provisions in this Article 7, Licensee is not obligated to reimburse costs incurred prior to and during the term of this Agreement in the preparation, filing, prosecution and maintenance of
patent applications and patents pertaining to [ * ] patent rights of UC Case No. [ * ] within Regents’ Patent Rights. Further, The Regents has no obligation to prosecute or maintain [ * ] patent rights of UC Case No. [ * ] within Regents’
Patent Rights. If The Regents elects to abandon [ * ] patent rights of UC Case No. [ * ] within Regents’ Patent Rights, then the consideration due to The Regents under this Agreement shall remain the same. 

 

	6.	Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement shall remain unchanged and in full force and effect. 

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their authorized officers on the dates written below: 

 

									
	MEDIVATION, INC.	  		  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By	  	  /s/ C. Patrick Machado
	  		  	By	  	  /s/ Claire T. Wake

	Name	  	C. Patrick Machado	  		  	Name	  	Claire T. Wake, Ph.D.
	Title	  	Senior Vice President and CFO	  		  	Title	  	Assistant Director, Licensing
	Date	  	June 10, 2006	  		  	Date	  	June 13, 2006
				
	 MEDIVATION PROSTATE

THERAPEUTICS, INC.
	  		  		  	
					
	By	  	  /s/ C. Patrick Machado
	  		  		  	
	Name	  	C. Patrick Machado	  		  		  	
	Title	  	Senior Vice President and CFO	  		  		  	
	Date	  	June 10, 2006	  		  		  	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2. 

 APPENDIX A 

(Third Amendment) 

REGENTS’ PATENT RIGHTS 

[ * ] 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3. 

 FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

UC Agreement Control No. 2006-04-0085 

This Fourth Amendment to Exclusive License Agreement (“Fourth Amendment”), dated as of July 17, 2007, is made by and among The Regents
of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary
of Medivation (“MPT”) (Medivation and MPT together “Licensee”) 
 BACKGROUND 

 

	A.	The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”), as amended on November 4, 2005, May 8,
2006 and June 12, 2007. 

  

	B.	Medivation has supported research in [ * ]’s laboratory at UCLA under a Sponsored Research Agreement with an Effective Date of [ * ] (the “Sponsored Research Agreement”). 

 

	C.	An invention has been developed at UCLA in the performance of the Sponsored Research Agreement, which is disclosed in UC Case No [ * ] entitled “[ * ],” by [ * ], employees of The Regents, [ * ], an employee
of Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of the University of California, Los Angeles at the time the invention was made, and [ * ], an employee of HHMI at the time the invention was made.

  

	D.	The Sponsored Research Agreement grants Medivation the first right to negotiate for a license to inventions made by The Regents in the performance of the Sponsored Research Agreement, and Medivation has exercised its
right and wishes to obtain an exclusive license to the invention noted in the preceding clause. 

  

	E.	Medivation as the parent corporation of MPT will benefit directly from the agreements made herein. 

  

	F.	The parties mutually intend to enter into this Fourth Amendment to amend the terms of the Exclusive License Agreement, as specified below. 

THEREFORE, the parties hereby agree as follows: 
  

	1.	Paragraph 1.1 (“Regents’ Patent Rights”) is deleted and replaced with the following, which is amended to include “UC Case No. [ * ]” in the parenthetical at the end of the
paragraph: 

  

	 	1.1	“Regents’ Patent Rights” means The Regents’ interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under
Paragraph 7.3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and
entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos. [ * ] and [ * ]) 

  

	2.	Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A attached to this Fourth Amendment, which is amended to include the patent applications to be filed under UC Case No. [ * ].

  

	3.	In consideration for the addition of the patent rights of UC Case No. [ * ] to the Exclusive License Agreement, Licensee will pay to The Regents a fee of [ * ] dollars ($[ * ]) within [ * ] of the Effective Date of this
Fourth Amendment. In addition, Licensee will pay a one-time milestone fee of [ * ] dollars ($[ * ]) upon [ * ] that would [ * ]. 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 1. 

	4.	Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement shall remain unchanged and in full force and effect. 

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their authorized officers on the dates written below: 

 

									
	MEDIVATION, INC.	  		  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By	  	  /s/ C. Patrick Machado
	  		  	By	  	  /s/ Claire T. Wake

	Name	  	C. Patrick Machado	  		  	Name	  	Claire T. Wake, Ph.D.
	Title	  	Senior Vice President and CFO	  		  	Title	  	Assistant Director, Licensing
	Date	  	August 8, 2007	  		  	Date	  	July 17, 2007
				
	MEDIVATION PROSTATE THERAPEUTICS, INC.	  		  		  	
					
	By	  	  /s/ C. Patrick Machado
	  		  		  	
	Name	  	C. Patrick Machado	  		  		  	
	Title	  	Senior Vice President and CFO	  		  		  	
	Date	  	August 8, 2007	  		  		  	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2. 

 APPENDIX A 

(Fourth Amendment) 

REGENTS’ PATENT RIGHTS 

[ * ] 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3. 

 FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

UC Agreement Control No. 2006-04-0085 

This Fifth Amendment to Exclusive License Agreement (“Fifth Amendment”), dated as of October 21, 2009, is made by and among The
Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and
subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”). 
 BACKGROUND 

 

	A.	The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”), as amended on November 4, 2005, May 8, 2006, June 12,
2006 and July 17, 2007. 

  

	B.	Medivation intends to grant an exclusive sublicense under the Exclusive License Agreement to the Designated Sublicensee (as defined in the Exclusive License Agreement as amended below). 

 

	C.	The parties mutually intend to enter into this Fifth Amendment to amend the terms of the Exclusive License Agreement, as specified below. 

THEREFORE, the parties hereby agree as follows: 
  

	1.	Article 1 is amended by the addition of the following new Paragraphs 1.15, 1.16 and 1.17: 

  

	 	1.15	“Designated Sublicense” means the Sublicense granted by Licensee to the Designated Sublicensee. 

  

	 	1.16	“Designated Sublicense Agreement” means the agreement entered into by Licensee and the Designated Sublicensee pursuant to which the Designated Sublicense is granted. 

 

	 	1.17	“Designated Sublicensee” means any Sublicensee that Licensee and The Regents agree in writing is a Designated Sublicensee for the purposes of this Agreement. 

 

	2.	Article 3 (Sublicenses) is amended to include a new Paragraph 3.6: 

  

	 	3.6	If this Agreement is terminated for any reason other than (a) [ * ], or (b) [ * ], in all cases except (a) and (b), Paragraph 3.5 will not apply, and instead this Paragraph 3.6 will apply: For as long as
the Designated Sublicensee Agreement remains in effect, the Designated Sublicense will [ * ] and [ * ] on [ * ], and from and after the effective date of such termination with respect to Licensee, the Designated Sublicensee will be deemed to have [
* ] and will become [ * ] all of [ * ] and [ * ] that arise as a result of [ * ] by [ * ] of such [ * ], including all [ * ]. 

  

	3.	Paragraphs 6.3d and 6.3e are deleted and replaced with the following: 

  

	 	6.3d	[ * ] a Licensed Product [ * ] by the [ * ] anniversary of the date of this Agreement. 

  

	 	6.3e	[ * ] of a Licensed Product by the [ * ] anniversary of the date of this Agreement. 

  

	4.	Article 7 (Patent Filing, Prosecution and Maintenance) is amended to include the following new Paragraph 7.8: 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 1. 

	 	7.8	The Regents represents that as of October 21, 2009, except as requested by Medivation in a notice provided pursuant to Paragraph 7.3, The Regents has not filed patent applications claiming or covering the Invention
or corresponding with the Regents’ Patent Rights in any foreign country, and that all of the foreign patents and patent applications claiming or covering the Invention or corresponding with the Regents’ Patent Rights are subject to this
Agreement (and are within the scope of the licenses and rights granted in Paragraphs 2.1 and 3.1). Notwithstanding the foregoing, no representation is made pursuant to this Section 7.8 with respect Patent No. [ * ], which The Regents is [ * ]
without [ * ]. 

  

	5.	The second sentence of Paragraph 8.1 is amended to include the following at the end of such sentence: 

. . . except that Licensee may [ * ] without consent of The Regents. 
  

	6.	Paragraph 8.2 is renumbered as Paragraph 8.2a. The third sentence of such Paragraph is deleted and replaced with the following: 

If joinder of The Regents is required by applicable law to perfect or maintain jurisdiction with respect to any such suit, then [ * ], The
Regents will join such suit, will consent to the jurisdiction of federal or state courts with respect to such suit, and will not oppose joinder in such suit, including on grounds of sovereign immunity. In the event of such required joinder, Licensee
will pay any costs incurred by The Regents arising out of such suit, including but not limited to, any legal fees of counsel that The Regents selects and retains to represent it in the suit. 

 

	7.	Article 8 (Patent Infringement) is amended to include the following new Paragraph 8.2b: 

  

	 	8.2b	Notwithstanding anything contained in this Article 8 to the contrary, if the Infringement Notice is predicated on the receipt of a notice of certification sent or filed pursuant to the U.S. “Drug Price Competition
and Patent Term Restoration Act” of 1984, including pursuant to 21 U.S.C. 355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV), or any equivalent or similar notice or certification in any foreign jurisdiction, claiming that the patent is invalid or
unenforceable or claiming that the patent will not be infringed by the Manufacture, use, marketing or sale of a product for which an application under the act is filed, then the Licensee may institute suit within the applicable timeframe required by
law and may, if required to perfect or maintain jurisdiction with respect to such suit, name The Regents as a co-plaintiff in such suit, [ * ]. In such circumstance, The Regents will use best efforts to [ * ] within [ * ] of the Infringement Notice,
and will notify Licensee no later than such [ * ]. Prior to initiating the suit, the Licensee will consult with The Regents to obtain its input with respect to the proposed suit, and will consider such input in good faith. Without limitation to the
foregoing and [ * ], The Regents agree to cooperate with respect to such suit if named as a co-plaintiff, including by participating as a party plaintiff in any such suit, joining in such suit, consenting to the jurisdiction of federal or state
courts, and not opposing joinder, including on grounds of sovereign immunity. The Regents may voluntarily join any such suit initiated solely by the Licensee at the Regents’ own expense, but may not thereafter commence suit against the
infringer for the acts of infringement that are the subject of the Licensee’s suit or any judgment rendered in the suit. If The Regents is named by the Licensee as a co-plaintiff in such a suit pursuant to the first sentence of this Paragraph
8.2b, then the Licensee will pay any costs incurred by The Regents arising out of such suit, including but not limited to, any legal fees of counsel that The Regents selects and retains to represent it in the suit. The Regents hereby acknowledges
that the rights conferred on the Licensee pursuant to Paragraphs 8.1 and 8.2 may be exercised by a Sublicensee designated by the Licensee (including the Designated Sublicensee). 

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2. 

	8.	Article 30 is amended by the addition of the following new Paragraph 30.2: 

  

	 	30.2	The Designated Sublicensee is an intended third-party beneficiary of this Agreement and certain of its provisions, including Paragraph 3.6, are for the benefit of the Designated Sublicensee and are enforceable by the
Designated Sublicensee in its own name. 

  

	9.	Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement remain unchanged and in full force and effect. 

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their authorized officers on the dates written below: 

 

			
	THE REGENTS OF THE UNIVERSITY
	OF CALIFORNIA
		
	By	 	  /s/ Claire T. Wake

	Name:	 	Claire T. Wake
	Title:	 	Assistant Director, Licensing
	Date:	 	October 21, 2009
	
	MEDIVATION, INC.
		
	By	 	  /s/ C. Patrick Machado

	Name:	 	C. Patrick Machado
	Title:	 	CFO
	Date:	 	October 21, 2009
	
	MEDIVATION PROSTATE THERAPEUTICS, INC.
		
	By	 	  /s/ C. Patrick Machado

	Name:	 	C. Patrick Machado
	Title:	 	CFO
	Date:	 	October 21, 2009

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]